JOURNAL OF HEPATOLOGY | 卷:67 |
Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies | |
Article | |
Bruix, Jordi1  Cheng, Ann-Lii2  Meinhardt, Gerold3  Nakajima, Keiko3  De Sanctis, Yoriko3  Llovet, Josep1,4,5  | |
[1] Univ Barcelona CIBERehd, IDIBAPS, BCLC Hosp Clin Barcelona, Hepat Oncol, Barcelona, Spain | |
[2] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan | |
[3] Bayer HealthCare Pharmaceut, Whippany, NJ USA | |
[4] Icahn Sch Med Mt Sinai, Mt Sinai Liver Canc Program, New York, NY USA | |
[5] ICREA, Barcelona, Catalonia, Spain | |
关键词: Hepatocellular carcinoma; Sorafenib; Prognostic; Predictive; Overall survival; | |
DOI : 10.1016/j.jhep.2017.06.026 | |
来源: Elsevier | |
【 摘 要 】
Background & Aims: Sorafenib, an oral multikinase inhibitor, significantly prolonged overall survival (OS) vs. placebo in patients with unresectable hepatocellular carcinoma (HCC) in two phase III studies, SHARP (Sorafenib HCC Assessment Randomized Protocol) and Asia Pacific (AP). To assess prognostic factors for HCC and predictive factors of sorafenib benefit, we conducted a pooled exploratory analysis from these placebo-controlled phase III studies. Methods: To identify potential prognostic factors for OS, univariate and multivariate (MV) analyses were performed for baseline variables by Cox proportional hazards model. Hazard ratios (HRs) and median OS were evaluated across pooled subgroups. To assess factors predictive of sorafenib benefit, the interaction term between treatment for each subgroup was evaluated by Cox proportional hazard model. Results: In 827 patients (448 sorafenib; 379 placebo) analyzed, strong prognostic factors for poorer OS identified from MV analysis in both treatment arms were presence of macroscopic vascular invasion (MVI), high alpha-fetoprotein (AFP), and high neutrophil-to-lymphocyte ratio (NLR; <= vs. > median [3.1]). Sorafenib OS benefit was consistently observed across all subgroups. Significantly greater OS sorafenib benefit vs. placebo was observed in patients without extrahepatic spread (EHS; HR, 0.55 vs. 0.84), with hepatitis C virus (HCV) (HR, 0.47 vs. 0.81), and a low NLR (HR, 0.59 vs. 0.84). Conclusions: In this exploratory analysis, presence of MVI, high AFP, and high NLR were prognostic factors of poorer OS. Sorafenib benefit was consistently observed irrespective of prognostic factors. Lack of EHS, HCV, and lower NLR were predictive of a greater OS benefit with sorafenib. (C) 2017 European Association for the Study of the Liver. Published by Elsevier B.V.
【 授权许可】
Free
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
10_1016_j_jhep_2017_06_026.pdf | 2570KB | download |